DGIdb - UGT1A9 Gene Record

UGT1A9 54600 Druggable Genome

Alternate Names:

54600
UDP GLUCURONOSYLTRANSFERASE FAMILY 1 MEMBER A9
UGT1A9
HLUGP4
LUGP4
UDPGT
UDPGT 1-9
UGT-1I
UGT1-09
UGT1-9
UGT1.9
UGT1A9S
UGT1AI
UGT1I
606434
12541
ENSG00000241119
OTTHUMG00000059124
PA419
UDP glucuronosyltransferase 1 family, polypeptide A9
BE0003538
O60656
UDP-glucuronosyltransferase 1-9

Gene Info:

Has Variant Annotation	true
Is VIP	false
Gene Biotype	PROTEIN_CODING

(3 More Sources)

Gene Categories: Category Details

DRUGGABLE GENOME
ENZYME

Publications:

Mano et al., 2006, In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid., Biopharm Drug Dispos
Wang H et al., 2014, Association analysis of UGT1A genotype and haplotype with SN-38 glucuronidation in human livers., Pharmacogenomics
Han JY et al., 2009, Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer., Lung Cancer
Han JY et al., 2006, Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin., J Clin Oncol
Gagné JF et al., 2002, Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)., Mol Pharmacol
Iwuchukwu OF et al., 2014, Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting., Pharmacogenomics
Uesawa et al., 2007, Identification of the human liver UDP-glucuronosyltransferase involved in the metabolism of p-ethoxyphenylurea (dulcin)., Arch. Toxicol.
Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics
Boudou-Rouquette P et al., 2012, Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study., PLoS One
Mazaleuskaya LL et al., 2015, PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses., Pharmacogenet Genomics
Nakagawa T et al., 2012, Acetaminophen administration in a patient with Gilbert's syndrome., Pediatr Int
Mutlib AE et al., 2006, Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity., Chem Res Toxicol
Court MH et al., 2001, Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms., J Pharmacol Exp Ther
Korprasertthaworn P et al., 2012, Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity., Biochem Pharmacol
Lu Y et al., 2017, Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy., Eur J Clin Pharmacol
Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
Takahashi H et al., 2008, Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9)., Basic Clin Pharmacol Toxicol
Lévesque E et al., 2013, Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens., J Pharmacol Exp Ther
Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol
Carroll MB et al., 2017, Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose., Rheumatol Int

NIFLUMIC ACID UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Mano et al., 2006, In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid., Biopharm Drug Dispos

7-ETHYL-10-HYDROXYCAMPTOTHECIN UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Wang H et al., 2014, Association analysis of UGT1A genotype and haplotype with SN-38 glucuronidation in human livers., Pharmacogenomics

Han JY et al., 2009, Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer., Lung Cancer

Han JY et al., 2006, Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin., J Clin Oncol

SIMVASTATIN UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Iwuchukwu OF et al., 2014, Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting., Pharmacogenomics
PHENOLPHTHALEIN UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Uesawa et al., 2007, Identification of the human liver UDP-glucuronosyltransferase involved in the metabolism of p-ethoxyphenylurea (dulcin)., Arch. Toxicol.

SORAFENIB UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics

Boudou-Rouquette P et al., 2012, Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study., PLoS One

PHENOBARBITAL UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Mazaleuskaya LL et al., 2015, PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses., Pharmacogenet Genomics

ACETAMINOPHEN UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Mazaleuskaya LL et al., 2015, PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses., Pharmacogenet Genomics

Nakagawa T et al., 2012, Acetaminophen administration in a patient with Gilbert's syndrome., Pediatr Int

Mutlib AE et al., 2006, Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity., Chem Res Toxicol

SULFINPYRAZONE UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Korprasertthaworn P et al., 2012, Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity., Biochem Pharmacol

OXCARBAZEPINE UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lu Y et al., 2017, Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy., Eur J Clin Pharmacol

IBUPROFEN UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
PROPOFOL UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Takahashi H et al., 2008, Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9)., Basic Clin Pharmacol Toxicol

IRINOTECAN UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lévesque E et al., 2013, Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens., J Pharmacol Exp Ther

Han JY et al., 2009, Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer., Lung Cancer

Han JY et al., 2006, Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin., J Clin Oncol

METHOTREXATE UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol
ALLOPURINOL UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Carroll MB et al., 2017, Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose., Rheumatol Int
PHENYTOIN UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Mazaleuskaya LL et al., 2015, PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses., Pharmacogenet Genomics
FEBUXOSTAT UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Carroll MB et al., 2017, Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose., Rheumatol Int
RALTEGRAVIR UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
OXAZEPAM UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
RISPERIDONE UGT1A9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Ensembl: ENSG00000241119
- Version: 101_38
Alternate Names:

UGT1A9 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

PharmGKB: UGT1A9

Version: 18-August-2020

Alternate Names:

PA419 PharmGKB ID

Gene Info:

Publications:

Mazaleuskaya LL et al., 2015, PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses., Pharmacogenet Genomics

Takahashi H et al., 2008, Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9)., Basic Clin Pharmacol Toxicol

Carroll MB et al., 2017, Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose., Rheumatol Int

DrugBank: BE0003538

Version: 5.1.7

Alternate Names:

UGT1A9 DrugBank Gene Name

O60656 UniProt Accession

54600 Entrez Gene Id

Gene Info:

Publications:

Mano et al., 2006, In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid., Biopharm Drug Dispos

Uesawa et al., 2007, Identification of the human liver UDP-glucuronosyltransferase involved in the metabolism of p-ethoxyphenylurea (dulcin)., Arch. Toxicol.

NCI: UGT1A9
- Version: 14-September-2017
Alternate Names:

Gene Info:

Publications:

Shamaan et al., Vitamin C and aloe vera supplementation protects from chemical hepatocarcinogenesis in the rat., Nutrition
HingoraniCasas: ENSG00000241119
- Version: 31-May-2017
Alternate Names:

ENSG00000241119 Gene Symbol

UGT1A9 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
Pharos: UGT1A9
- Version: 03-September-2020
Alternate Names:

UDP-glucuronosyltransferase 1-9 Gene Name

O60656 UniProt ID

Gene Info:

Gene Categories:

ENZYME

Publications:
Tempus: UGT1A9
- Version: 11-November-2018
Alternate Names:

UGT1A9 Gene Symbol

Gene Info:

Publications:

UGT1A9	DrugBank Gene Name
O60656	UniProt Accession
54600	Entrez Gene Id

UGT1A9 Gene Record

UGT1A9 54600 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Mano et al., 2006, In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid., Biopharm Drug Dispos

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Iwuchukwu OF et al., 2014, Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting., Pharmacogenomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Uesawa et al., 2007, Identification of the human liver UDP-glucuronosyltransferase involved in the metabolism of p-ethoxyphenylurea (dulcin)., Arch. Toxicol.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics Boudou-Rouquette P et al., 2012, Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study., PLoS One

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Mazaleuskaya LL et al., 2015, PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Korprasertthaworn P et al., 2012, Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity., Biochem Pharmacol

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Lu Y et al., 2017, Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy., Eur J Clin Pharmacol

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Takahashi H et al., 2008, Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9)., Basic Clin Pharmacol Toxicol

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Carroll MB et al., 2017, Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose., Rheumatol Int

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Mazaleuskaya LL et al., 2015, PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Carroll MB et al., 2017, Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose., Rheumatol Int

Interaction Types & Directionality: n/a

Interaction Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Publications:

Ensembl: ENSG00000241119

Alternate Names: UGT1A9 Ensembl Gene Name

Gene Info: Gene Biotype PROTEIN_CODING

Publications:

PharmGKB: UGT1A9

Alternate Names: PA419 PharmGKB ID

Gene Info:

DrugBank: BE0003538

Alternate Names: UGT1A9 DrugBank Gene Name O60656 UniProt Accession 54600 Entrez Gene Id

Gene Info:

NCI: UGT1A9

Alternate Names:

Gene Info:

Publications: Shamaan et al., Vitamin C and aloe vera supplementation protects from chemical hepatocarcinogenesis in the rat., Nutrition

HingoraniCasas: ENSG00000241119

Alternate Names: ENSG00000241119 Gene Symbol UGT1A9 Ensembl Id

Gene Info:

Gene Categories: DRUGGABLE GENOME

Publications:

Pharos: UGT1A9

Interaction Types & Directionality:

n/a

Publications:

Mano et al., 2006, In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid., Biopharm Drug Dispos

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Iwuchukwu OF et al., 2014, Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting., Pharmacogenomics

Interaction Types & Directionality:

n/a

Publications:

Uesawa et al., 2007, Identification of the human liver UDP-glucuronosyltransferase involved in the metabolism of p-ethoxyphenylurea (dulcin)., Arch. Toxicol.

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics

Boudou-Rouquette P et al., 2012, Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study., PLoS One

Interaction Types & Directionality:

n/a

Publications:

Mazaleuskaya LL et al., 2015, PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Korprasertthaworn P et al., 2012, Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity., Biochem Pharmacol

Interaction Types & Directionality:

n/a

Publications:

Lu Y et al., 2017, Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy., Eur J Clin Pharmacol

Interaction Types & Directionality:

n/a

Publications:

Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Takahashi H et al., 2008, Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9)., Basic Clin Pharmacol Toxicol

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol

Interaction Types & Directionality:

n/a

Publications:

Carroll MB et al., 2017, Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose., Rheumatol Int

Interaction Types & Directionality:

n/a

Publications:

Mazaleuskaya LL et al., 2015, PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Carroll MB et al., 2017, Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose., Rheumatol Int

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Alternate Names:

UGT1A9 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Alternate Names:

PA419 PharmGKB ID

Alternate Names:

UGT1A9 DrugBank Gene Name

O60656 UniProt Accession

54600 Entrez Gene Id

Publications:

Shamaan et al., Vitamin C and aloe vera supplementation protects from chemical hepatocarcinogenesis in the rat., Nutrition

Alternate Names:

ENSG00000241119 Gene Symbol

UGT1A9 Ensembl Id

Gene Categories:

DRUGGABLE GENOME

Alternate Names:

UDP-glucuronosyltransferase 1-9 Gene Name

O60656 UniProt ID

Gene Categories:

ENZYME

Alternate Names:

UGT1A9 Gene Symbol